Table 1. Distribution of 298 NHL cases and 889 control subjects according to matching variables (Swiss HIV Cohort Study, 1984–2004).
|
NHL cases
|
Control subjects
|
|||
|---|---|---|---|---|
| N | (%) | N | (%) | |
| Centre | ||||
| Basel | 28 | (9.4) | 84 | (9.5) |
| Bern | 23 | (7.7) | 68 | (7.7) |
| Geneva | 42 | (14.1) | 125 | (14.1) |
| St Gallen | 9 | (3.0) | 27 | (3.0) |
| Ticino | 8 | (2.7) | 24 | (2.7) |
| Vaud | 57 | (19.1) | 169 | (19.0) |
| Zurich | 131 | (44.0) | 392 | (44.1) |
| Gender | ||||
| Male | 246 | (82.6) | 733 | (82.5) |
| Female | 52 | (17.5) | 156 | (17.6) |
| Age at enrolment (years) | ||||
| <30 | 83 | (27.9) | 249 | (28.0) |
| 30–44 | 141 | (47.3) | 425 | (47.8) |
| ⩾45 | 74 | (24.8) | 215 | (24.2) |
| CD4+ at enrolment (cells μl−1) | ||||
| <100 | 71 | (23.8) | 209 | (23.5) |
| 100–199 | 47 | (15.8) | 142 | (16.0) |
| 200–499 | 120 | (40.3) | 357 | (40.2) |
| ⩾500 | 60 | (20.1) | 181 | (20.4) |
| Duration of follow-up (months) | ||||
| <24 | 100 | (33.6) | 297 | (33.4) |
| 24–59 | 107 | (35.9) | 320 | (36.0) |
| ⩾60 | 91 | (30.5) | 272 | (30.6) |
NHL=non-Hodgkin's lymphoma.